Scott S. Tykodi, MD, PhD
Department of Medicine
Division of Oncology
Seattle Cancer Care Alliance
825 Eastlake Ave W, G4-810
Seattle, WA 98109
Specialty / Expertise
Melanoma and Kidney Cancer
The clinical application and translational study of natural or induced T cell immunity targeting renal cell carcinoma and other cancers.
Current Research Projects
Funded by: Argos Therapeutics
An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Funded by: Bristol Myers Squibb
A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Funded by: Bristol-Myers Squibb
A Phase 1, Open-label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
Funded by: Bristol-Myers Squibb
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors
Dr. Tykodi received his MD and PhD from the Washington University School of Medicine, St. Louis, MO. He completed his Internal Medicine Residency at the Barnes-Jewish Hospital, Washington University, St. Louis, MO. He was a Post-Doctoral Fellow in Medical Oncology at the University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA.
Wrangle J., W. Wang, A. Koch, H. Easwaran, H.P. Mohammad, F. Vendetti, W. Vancriekinge, T. Demeyer, Z. Du, P. Parsana, K. Rodgers, R.W. Yen, C.A. Zahnow, J.M. Taube, J.R. Brahmer, S. S. Tykodi, K. Easton, R.D. Carvajal, P.A. Jones, P.W. Laird, D.J. Weisenberger, S. Tsai, R.A. Juergens, S.L. Topalian, C.M. Rudin, M.V. Brock, D. Pardoll, and S.B. Baylin. Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget. 2013. 4(11):2067-79.
Torikai. H., A. Reik , F. Soldner, E. H. Warren, C. Yuen, Y. Zhou, D. L. Crossland, H. Huls, N. Littman, Z. Zhang, S. S. Tykodi, P. Kebriaei, D. A. Lee, J. C. Miller, E. J. Rebar, M. C. Holmes, R. Jaenisch, R. E. Champlin, P. D. Gregory, and L. J.N. Cooper. Towards Eliminating HLA Class I Expression to Generate Universal Cells from Allogeneic Donors. Blood. 2013. 122(8):1341-9.
Goodridge, J. P., N. Lee, A. Burian, C. Pyo,
Tykodi, S. S. Progress and Potential of Immune Checkpoint Blockade for Treating Advanced Renal Cell Carcinoma. Immunother. 2013. 5(6):607-19.
Tykodi, S. S., S. Satoh, J. D. Deming, J. Chou, R. Harrop, and E. H. Warren. CD8+ T Cell Clones Specific for the 5T4 Antigen Target Renal Cell Carcinoma Tumor-Initiating Cells in a Murine Xenograft Model. J Immunother. 2012. 35(7):523-33.
Brahmer, J. R., S. S. Tykodi*, L. Q. M. Chow, W. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T. S. Salay, S. Alaparthy, J. F. Grosso, A. J. Korman, S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A.Gupta, and J. M. Wigginton. Safety and Activity of Anti-PD-L1 (BMS-936559) in Patients with Advanced Solid Tumors. N Engl J Med. 2012 366:2455-65. (*Co-first author)
Tykodi, S. S., B. M. Sandmaier, E. H. Warren, and J. A. Thompson. Allogeneic Hematopoietic Cell Transplantation for Renal Cell Carcinoma: Ten Years After. Expert Opin. Biol. Ther. 2011. 11(6):763-73.
Tykodi, S. S., L. N. Voong and E. H. Warren. Combining Allogeneic Immunotherapy with an mTOR Inhibitor for Advanced Renal Cell Carcinoma. BMT. 2010. 45:1360-1362.
Bhatia, S., S. S. Tykodi, and J. A. Thompson. Treatment of Metastatic Melanoma: An Overview. Oncology. 2009. 23:488-496.
Tykodi, S. S., J. A. Thompson. Development of Modified Vaccinia Ankara-5T4 as Specific Immunotherapy for Advanced Human Cancer. Expert Opin. Biol. Ther. 2008. 8:1947-1953.
Tykodi, S. S., N. Fujii, N. Vigneron, S. M. Lu, J. K. Mito, M. X. Miranda, J. Chou, L. N. Voong, J. A. Thompson, B. M. Sandmaier, P. Cresswell, B. Van den Eynde, S. R. Riddell and E. H. Warren. C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clin Cancer Res. 2008. 14:5260-5269.
Warren, E. H., N. J. Vigneron, M. A. Gavin, P. G. Coulie, V. Stroobant, A. Dalet, S. S. Tykodi, S. M. Xuereb, J. M. Mito, S. R. Riddell, and B. J. Van den Eynde. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science. 2006. 313:1444-1447.
Tykodi, S. S., E. H. Warren, J. A. Thompson, S. R. Riddell, R. W. Childs, B. E. Otterud, M. F. Leppert, R. Storb and B. M. Sandmaier. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 2004. 10:7799-7811.
Warren, E. H., S. S. Tykodi, M. Murata, B. M. Sandmaier, R. Storb, E. Jaffee, R. Childs, J. A. Thompson, P. D. Greenberg, and S. R. Riddell. T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy. 2002. 4:441.
Fan, R., S. S. Tykodi*, and T. J. Braciale. Recognition of a sequestered self peptide by influenza virus-specific CD8+ cytolytic T lymphocytes. J. Immunol. 2000. 164:1669-80. (*Co-first author)
Cao, W., S. S. Tykodi, M. T. Esser, V. L. Braciale, and T. J. Braciale. Partial activation of CD8+ T cells by a self-derived peptide. Nature. 1995. 378:295-8.
Last updated: February 2014